Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients

被引:115
作者
Wozniacka, A
Lesiak, A
Narbutt, J
McCauliffe, DP
Sysa-Jedrezejowska, A
机构
[1] Med Univ Lodz, Dept Dermatol, PL-94107 Lodz, Poland
[2] Rutland Reg Med Ctr, Dept Med, Rutland, VT USA
关键词
chloroquine; cytokine; interleukin; lupus erythematosus; tumor necrosis factor;
D O I
10.1191/0961203306lu2299oa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic lupus erythematosus (SLE) is an autoimmune disease with a complex pathogenesis. Published data have revealed that serum levels of proinflammatory cytokines are increased in SLE patients. The aim of our study was to evaluate whether monotherapy with chloroquine phosphate affects IL-1 beta, IL-6, IL-18 and TNF-alpha serum levels in SLE patients. The study group consisted of 25 SLE patients with mild or moderate disease activity and 25 age- and sex-matched healthy control subjects. In SLE patients the cytokine levels were measured just before and three months after starting chloroquine treatment at a dose of 125 mg twice daily. Although the majority of SLE patients had a low systemic lupus activity measure (SLAM) index, the levels of IL-6, IL-18 and TNF-alpha were significantly higher than in the control group. After three-months of chloroquine therapy the mean level of IL-6, IL-18 and TNF-alpha decreased significantly. Minimal erythema doses (MEDs) were significantly increased in SLE patients after three months of chloroquine therapy. The results indicate that chloroquine treatment lowers some proinflammatory cytokines and may provide a photoprotective effect.
引用
收藏
页码:268 / 275
页数:8
相关论文
共 63 条
[21]   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [J].
Hochberg, MC .
ARTHRITIS AND RHEUMATISM, 1997, 40 (09) :1725-1725
[22]   Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus [J].
Housman, TS ;
Jorizzo, JL ;
McCarty, MA ;
Grummer, SE ;
Fleischer, AB ;
Sutej, PG .
ARCHIVES OF DERMATOLOGY, 2003, 139 (01) :50-54
[23]   A synthetic peptide derived from bactericidal/permeability-increasing protein neutralizes endotoxin in vitro and in vivo [J].
Jiang, Z ;
Hong, Z ;
Wei, G ;
Gong, XY ;
Lu, GF ;
Lu, YM ;
Xiao, GX .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2004, 4 (04) :527-537
[24]  
KARRES I, 1998, AM J PHYSIOL, V43, pR1058
[25]   HUMAN KERATINOCYTES ARE A SOURCE FOR TUMOR-NECROSIS-FACTOR-ALPHA - EVIDENCE FOR SYNTHESIS AND RELEASE UPON STIMULATION WITH ENDOTOXIN OR ULTRAVIOLET-LIGHT [J].
KOCK, A ;
SCHWARZ, T ;
KIRNBAUER, R ;
URBANSKI, A ;
PERRY, P ;
ANSEL, JC ;
LUGER, TA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1990, 172 (06) :1609-1614
[26]   DOSAGE OF ANTIMALARIAL DRUGS FOR CHILDREN WITH JUVENILE RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS - CLINICAL STUDY WITH DETERMINATION OF SERUM CONCENTRATIONS OF CHLOROQUINE AND HYDROXYCHLOROQUINE [J].
LAAKSONEN, AL ;
KOSKIAHDE, V ;
JUVA, K .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1974, 3 (02) :103-108
[28]   RELIABILITY AND VALIDITY OF 6 SYSTEMS FOR THE CLINICAL-ASSESSMENT OF DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
LIANG, MH ;
SOCHER, SA ;
LARSON, MG ;
SCHUR, PH .
ARTHRITIS AND RHEUMATISM, 1989, 32 (09) :1107-1118
[29]  
Liew FY, 2002, ANN RHEUM DIS, V61, P100
[30]   CYTOKINE ABNORMALITIES IN HUMAN LUPUS [J].
LINKERISRAELI, M .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1992, 63 (01) :10-12